Triple-Combination Therapy Prolongs Progression-Free Survival in Elderly Patients With Multiple Myeloma: Presented at EHA
By Jenny Powers
BARCELONA, Spain -- June 16, 2010 -- Patients aged 65 years and older experienced significantly longer progression-free survival (PFS) and improved overall survival (OS) after first-line treatment with melphalan, prednisone, and thalidomide (MPT), compared with melphalan and prednisone.
Maintenance therapy with thalidomide extended PFS for patients with multiple myeloma, but such therapy did not result in a similar benefit for OS, according to results from a European study.
From August 2001 to October 2007, researchers at 26 clinics in central and eastern Europe recruited 249 patients who were not eligible for autologous stem cell transplantation. Those patients were treated with thalidomide-dexamethasone or melphalan-prednisolone...
(Reuters) - Celgene Corp is set to showcase its research pipeline to Wall Street on Thursday -- hoping to prove that it has a long-term growth story that goes beyond its flagship multiple myeloma drug Revlimid.
The company will provide details on its experimental drugs for lung cancer; chemotherapy-induced anemia; multiple myeloma; Crohn's disease, a gastrointestinal disorder; psoriasis, a skin disorder; and psoriatic...
WALTHAM, Mass., March 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the multiple myeloma drug market will more than double from $2.1...
Adding bortezomib, thalidomide to standard multiple myeloma treatments improved response in older patients
HemOnc today
Posted December 5, 2009
Pairing bortezomib with either melphalan/prednisone or thalidomide/prednisone resulted in favorable response rates among older patients with multiple myeloma, according to data presented at the 51st ASH Annual Meeting.
In addition, lowering the doses of the therapies at induction in favor of maintenance therapy...
